XTX Topco Ltd bought a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund bought 45,917 shares of the biopharmaceutical company's stock, valued at approximately $1,561,000. XTX Topco Ltd owned 0.07% of Celldex Therapeutics at the end of the most recent quarter.
Other large investors have also modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Celldex Therapeutics in the second quarter valued at approximately $76,000. KBC Group NV grew its stake in shares of Celldex Therapeutics by 31.2% during the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company's stock worth $71,000 after purchasing an additional 495 shares during the period. Los Angeles Capital Management LLC increased its holdings in shares of Celldex Therapeutics by 9.5% in the 2nd quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company's stock valued at $273,000 after purchasing an additional 638 shares in the last quarter. Quest Partners LLC lifted its stake in shares of Celldex Therapeutics by 1,364.9% in the second quarter. Quest Partners LLC now owns 7,383 shares of the biopharmaceutical company's stock valued at $273,000 after purchasing an additional 6,879 shares during the period. Finally, AQR Capital Management LLC boosted its holdings in Celldex Therapeutics by 23.7% during the second quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company's stock worth $291,000 after buying an additional 1,504 shares in the last quarter.
Insider Transactions at Celldex Therapeutics
In related news, CEO Anthony S. Marucci bought 11,500 shares of the stock in a transaction that occurred on Monday, November 11th. The stock was purchased at an average cost of $26.82 per share, for a total transaction of $308,430.00. Following the completion of the acquisition, the chief executive officer now owns 40,284 shares in the company, valued at $1,080,416.88. This trade represents a 39.95 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 3.80% of the company's stock.
Analyst Upgrades and Downgrades
CLDX has been the subject of a number of research reports. Wolfe Research downgraded shares of Celldex Therapeutics from an "outperform" rating to a "peer perform" rating in a research report on Friday, September 27th. The Goldman Sachs Group assumed coverage on Celldex Therapeutics in a research report on Monday, September 30th. They set a "neutral" rating and a $45.00 target price on the stock. HC Wainwright restated a "buy" rating and issued a $80.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, November 20th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research report on Monday, September 16th. Finally, Wells Fargo & Company upgraded shares of Celldex Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Thursday, September 26th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $62.25.
View Our Latest Stock Analysis on CLDX
Celldex Therapeutics Trading Down 1.4 %
Shares of Celldex Therapeutics stock traded down $0.37 during mid-day trading on Monday, hitting $26.40. 1,621,708 shares of the stock were exchanged, compared to its average volume of 887,249. The company has a 50-day simple moving average of $27.65 and a 200 day simple moving average of $33.90. The stock has a market capitalization of $1.75 billion, a price-to-earnings ratio of -10.27 and a beta of 1.57. Celldex Therapeutics, Inc. has a twelve month low of $22.93 and a twelve month high of $53.18.
Celldex Therapeutics Company Profile
(
Free Report)
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
Further Reading
Before you consider Celldex Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.
While Celldex Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
